<DOC>
	<DOCNO>NCT02321306</DOCNO>
	<brief_summary>Open-label , multicenter study adult Primary Biliary Cirrhosis ( PBC ) design evaluate long-term safety tolerability daily dose LUM001 .</brief_summary>
	<brief_title>An Open-label Study Evaluate Long-term Safety Tolerability LUM001 Patients With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This open-label study subject PBC previously complete LUM001 201 ( CLARITY ) study . The study design investigate long-term safety tolerability LUM001 treatment , daily dose 2 year . Changes time , compare baseline , liver enzymes , biochemical marker associate PBC , pruritus , quality life measure also assess .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<criteria>1 . Completed core treatment protocol LUM001 treatment Primary Biliary Cirrhosis . 2 . Ability understand willingness sign inform consent/assent prior initiation study procedure . 1 . Presence advance liver disease . 2 . History nonadherence subject 's participation core LUM001 treatment protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>